IL-12 Is Both Required and Sufficient for Initiating T Cell Reactivity to a Class I-Restricted Tumor Peptide (P815AB) Following Transfer of P815AB-Pulsed Dendritic Cells

Journal of Immunology

Volumn 157, Issue 4, 1996, Pages 1589-1597

  Bianchi, Roberta ^a   Grohmann, Ursula ^a   Belladonna, Maria Laura ^a   Silla, Silvia ^a   Fallarino, Francesca ^a   Ayroldi, Emira ^a   Fioretti, Maria Cristina ^a   Puccetti, Paolo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; H2 ANTIGEN; HISTOCOMPATIBILITY ANTIGEN H 2D(B); HISTOCOMPATIBILITY ANTIGEN H-2D(B); HLA ANTIGEN CLASS 2; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 4; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TETANUS TOXIN; TUMOR ANTIGEN; TUMOR PROTEIN; TUMOR REJECTION ANTIGEN P815A, MOUSE;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DBA MOUSE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MALE; MOLECULAR GENETICS; MOUSE; PATHOLOGY; PHYSIOLOGY; SARCOMA; SECRETION; SKIN TEST; TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; LYMPHOCYTE DEPLETION; MALE; MAST-CELL SARCOMA; MICE; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SKIN TESTS; T-LYMPHOCYTES, CYTOTOXIC; TETANUS TOXIN;

EID: 0030586543     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Scott, P. 1993. IL-12: initiation cytokine for cell-mediated immunity. Science 260:547.
2. Van den Eynde, B., B. Lethé, A. Van Pel, E. De Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173:1373.
3. Boon, T., J.-C. Cerottini, B. Van den Eynde, P. Van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
4. Uyttenhove, C., J. Maryansky, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1040.
5. Lethé, B., B. Van den Eynde, A. Van Pel, G. Corradin, and T. Boon. 1992. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22:2283.
6. Kündig, T. M., A. Althage, H. Hengartner, and R. M. Zinkernagel. 1992. Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci USA 89: 7757.
7. + T cell reactivity. Eur. J. Immunol. 24:1446.
8. - or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur. J. Immunol. 25:2797.
9. Gajewski, T. F., J.-C. Renhauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6 and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154:5637.
10. Trinchieri, G. 1994. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008.
11. Brunda, M. J., and M. K. Gately. 1995. Interleukin-12: potential role in cancer therapy. In Important Advances in Oncology 1995. V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds. Lippincott Co, Philadelphia, p. 3.
12. Zitvogel, L., H. Tahara, P. D. Robbins, W. J. Storkus, M. Clarke, M. Nalesnik, M. K. Gately, and M. T. Lotze. 1995. Cancer immunotherapy of established tumors with interleukin-12 (IL-12): effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393.
13. Noguchi, Y., E. C. Richards, Y.-T. Chen, and L. J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established MethA sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
14. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
15. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
16. Hegde, S. P., J. J. Bright, S. Kausalya, and A. Khar. 1995. AK-5 tumor-induced expression of interleukin-12: a role of IL-12 in NK-mediated AK-5 regression. Cell. Immunol. 162:241.
17. Romani, L., A. Mencacci, L. Tonnetti, R. Spaccapelo, E. Cenci, S. Wolf, P. Puccetti, and F. Bistoni. 1994. Interleukin-12 but not interferon-γ production correlates with induction of T helper type-1 phenotype in murine candidiasis. Eur. J. Immunol. 24:909.
18. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope-derived peptide-pulsed dendritic cells. Int. Immunol. 5:849.
19. Grohmann, U., P. Puccetti, M. L. Belladonna, F. Fallarino, R. Bianchi, L. Binaglia, K. Sagakuchi, M. G. Mage, E. Appella, and M. C. Fioretti. 1995. Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor. J. Immunol. 154:4630.
20. Grohmann, U., S. J. Ullrich, M. G. Mage, E. Appella, M. C. Fioretti, P. Puccetti, and L. Romani. 1990. Identification and immunogenic properties of an 80-kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. Eur. J. Immunol. 20:629.
21. Grohmann, U., L. Romani, L. Binaglia, M. C. Fioretti, and P. Puccetti. 1991. Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. J. Immunol. Methods 137:9.
22. Romani, L., A. Mencacci, L. Tonnetti, R. Spaccapelo, E. Cenci, P. Puccetti, S. F. Wolf, and F. Bistoni. 1994. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J. Immunol. 152:5167.
23. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547.
24. Heinzel, F. P., D. S. Schoenhaut, R. Rerko, L. E. Rosser, and M. K. Gately. 1994. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1505.
25. Sypek, J. P., C. L. Chung, S. E. H. Mayor, S. J. Subramanyan, S. J. Goldman, D. S. Sieburth, S. F. Wolf, and R. G. Schaub. 1994. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1797.
26. Wolf, S. F., D. Sieburth, and J. Sypek. 1994. Interleukin 12: a key modulator of immune function. Stem Cells 12:154.
27. Heinzel, F. P. 1995. Th1 and Th2 cells in the cure and pathogenesis of infectious diseases. Curr. Opin. Infect. Dis. 8:151.
28. Romagnani, S. 1994. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 12:227.
29. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
30. Afonso, L. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235.
31. H2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol. 3:237.
32. + T cells in cancer immunotherapy. Curr. Opin. Immunol. 6:741.
33. Pardoll, D. M. 1993. Cancer vaccines. Immunol. Today 14:310.
34. Ostrand-Rosenberg, S. 1994. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6:722.
35. + T cells. J. Immunol. 154:5071.
36. + T cells. Eur. J. Immunol. 24: 343.
37. + T cells. Annu. Rev. Immunol. 12:635.
38. + T cells into IL-4-secreting cells. J. Immunol. 152:5180.
39. Pfeiffer, C., U. J. Stein, S. Southwood, H. Ketelaar, A. Sette, and K. Bottomly. 1994. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J. Exp. Med. 181:1569.
40. Skeen, M. J., M. A. Miller, T. M. Shinnick, and H. K. Ziegler. 1996. Regulation of murine macrophage IL-12 production: activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J. Immunol. 156:1196.
41. L. Romani, F. Bistoni, A. Mencacci, E. Cenci, R. Spaccapelo, and P. Puccetti. 1995. IL-12 in Candida albicans infections. Res. Immunol. 146:532.
42. Glasebrook, A. L., and F. W. Fitch. 1979. T cell lines which cooperate in generation of specific cytolytic activity. Nature 278:171.
43. Reissmann, S., and G. Greiner. 1992. Hydrolysis of peptide esters by different enzymes. Int. J. Pept. Protein Res. 40:110.
44. Adorini, L., E. Appella, G. Doria, and Z. A. Nagy. 1988. Mechanisms influencing the immunodominance of T cell determinants. J. Exp. Med. 168:2091.
45. Li, W. F., M. D. Fan, C. B. Pan, and M. Z. Lai. 1992. T cell epitope selection: dominance may be determined by both affinity for major histocompatibility complex and stoichiometry of epitope. Eur. J. Immunol. 22:943.
46. Shu, U., M. Kiniwa, C. Y. Wu, C. Maliszewski, N. Vezzio, J. Hakimi, M. Gately, and G. Delespesse. 1995. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur. J. Immunol. 25:1125.
47. Kennedy, M. K., K. S. Picha, W. C. Fanslow, K. H. Grabstein, M. R. Alderson, K. N. Clifford, W. A. Chin, and K. M. Mohler. 1996. CD40-CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur. J. Immunol. 26:370.
48. Ma, X., A. D'Andrea, M. Kubin, M. Aste-Amezaga, A. Sartori, J. Monteiro, L. Showe, M. Wysocka, and G. Trinchieri. 1995. Production of inlerleukin-12. Res. Immunol. 146:432.